WP 5: European multi-centre phase-I/II clinical trial
The objective of WP5 will be the implementation and execution of a multi-centre phase-I/II clinical trial in HCC patients at five different clinical sites within Europe. It will investigate the safety, feasibility and biological efficacy of a novel approach of the multi-target, multi-epitope and multi-HLA “off-the-shelf” vaccine as well as the additional actively personalised vaccination (APVAC) in a subset of patients. The trial will be conducted according to all relevant legislation and guidance including ICH/GCP guidelines.
Leader: Bruno Sangro – NAVAR